isoniazid has been researched along with Cirrhosis in 10 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Excerpt | Relevance | Reference |
---|---|---|
"Fibrosis is one of the major causes of post-treatment morbidity in tuberculosis." | 1.31 | Biochemical and histochemical changes pertaining to active and healed cutaneous tuberculosis. ( Jayasankar, K; Ramanathan, VD; Shakila, H; Umapathy, KC, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 5 (50.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
Authors | Studies |
---|---|
Kim, LB | 1 |
Putyatina, AN | 1 |
Russkikh, GS | 1 |
Shkurupy, VA | 1 |
Gengenbacher, M | 1 |
Duque-Correa, MA | 1 |
Kaiser, P | 1 |
Schuerer, S | 1 |
Lazar, D | 1 |
Zedler, U | 1 |
Reece, ST | 1 |
Nayyar, A | 1 |
Cole, ST | 1 |
Makarov, V | 1 |
Barry Iii, CE | 1 |
Dartois, V | 1 |
Kaufmann, SHE | 1 |
Gourishankar, A | 1 |
Navarro, F | 1 |
Debroy, AN | 1 |
Smith, KC | 1 |
Gil, O | 1 |
Díaz, I | 1 |
Vilaplana, C | 1 |
Tapia, G | 1 |
Díaz, J | 1 |
Fort, M | 1 |
Cáceres, N | 1 |
Pinto, S | 1 |
Caylà, J | 1 |
Corner, L | 1 |
Domingo, M | 1 |
Cardona, PJ | 2 |
Kubota, M | 1 |
Shinoda, A | 1 |
Iguchi, K | 1 |
Takahashi, Y | 1 |
Usui, S | 1 |
Kiho, T | 1 |
Hirano, K | 1 |
Ivanyi, J | 1 |
Filimonov, PN | 1 |
Shkurupiĭ, VA | 1 |
Kurunov, IuN | 1 |
Pupyshev, AB | 1 |
Panasenko, SG | 1 |
Bruña-Romero, O | 1 |
González-Aseguinolaza, G | 1 |
Hafalla, JC | 1 |
Tsuji, M | 1 |
Nussenzweig, RS | 1 |
Jayasankar, K | 1 |
Shakila, H | 1 |
Umapathy, KC | 1 |
Ramanathan, VD | 1 |
Welch, NG | 1 |
Winkler, DA | 1 |
Thissen, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Inf[NCT01136161] | Phase 2 | 95 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner[NCT00904956] | 12 participants (Anticipated) | Observational | 2009-11-30 | Recruiting | |||
A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.[NCT02485912] | Phase 1 | 40 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.~The following parameters will be assessed for both groups:~Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination~Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination~Occurrence of unsolicited adverse events for 28 days following the vaccination~Change from baseline for safety laboratory measures~Occurrence of serious adverse events during the whole study duration" (NCT02485912)
Timeframe: 26 weeks
Intervention | participants (Number) |
---|---|
Group 1 | 20 |
Group 2 | 20 |
"Ebolavirus specific immunogenicity will be assessed by a variety of immunological assays. The primary immunogenicity outcome measures are ELISA and neutralization antigen-specific assays for antibody responses and intracellular cytokine staining (ICS) assay for T cell responses.~Exploratory outcome measures will include ex-vivo ELISPOT, plasma blast assays and flow cytometry performed with research samples collected at different study timepoints as well as other immunogenicity assays throughout the study. An evaluation of genetic factors associated with immune responses may be performed as exploratory evaluation. Vaccine-induced mRNA expression profiles during 1 week after vaccination may also be performed as an exploratory evaluation." (NCT02485912)
Timeframe: 26 weeks
Intervention | participants (Number) |
---|---|
Group 1 | 20 |
Group 2 | 20 |
2 reviews available for isoniazid and Cirrhosis
Article | Year |
---|---|
The secret trumps, impelling the pathogenicity of tubercle bacilli.
Topics: Aerosols; Antigen Presentation; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Cyto | 2011 |
Antifibrotic strategies for medical devices.
Topics: Animals; Biocompatible Materials; Delayed-Action Preparations; Drug Implants; Fibrosis; Foreign-Body | 2020 |
8 other studies available for isoniazid and Cirrhosis
Article | Year |
---|---|
Content of the Major Extracellular Matrix Components of the Liver and Lungs in Mice with Chronic BCG-Granulomatosis Treated with Liposome-Encapsulated Dextrazide.
Topics: Animals; BCG Vaccine; Dextrans; Drug Combinations; Extracellular Matrix; Fibrosis; Glycosaminoglycan | 2021 |
NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Fibrosis; Foam Cells; Humans; Hypoxia; Isoni | 2017 |
Isoniazid hepatotoxicity with clinical and histopathology correlate.
Topics: Adolescent; Biopsy; Female; Fibrosis; Humans; Inflammation; Isoniazid; Liver; Lymphocytes | 2014 |
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.
Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz | 2010 |
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.
Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz | 2010 |
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.
Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz | 2010 |
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.
Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz | 2010 |
Up-regulation of the lysyl hydroxylase 2 gene by acetaminophen and isoniazid is modulated by transcription factor c-Myb.
Topics: Acetaminophen; Binding Sites; Blotting, Western; Chemical and Drug Induced Liver Injury; Fibrosis; G | 2010 |
[Examining fibrotic process in lung during treatment of chronic murine tuberculosis with lysosomotropic drug isonaizid].
Topics: Animals; Antitubercular Agents; Chronic Disease; Disease Models, Animal; Fibrosis; Follow-Up Studies | 1999 |
Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen.
Topics: Animals; Antibody Formation; Antimalarials; BCG Vaccine; Disease Models, Animal; Fibrosis; Humans; I | 2001 |
Biochemical and histochemical changes pertaining to active and healed cutaneous tuberculosis.
Topics: Antitubercular Agents; Biopsy; Collagen; Elastin; Fibronectins; Fibrosis; Humans; Immunohistochemist | 2002 |